B Cell Depletion and SARS-CoV-2 Vaccine Responses in Neuroimmunologic Patients.

"Potential Conflicts of Interest Roche manufactures Ocrelizumab, which is studied in this paper. B.K., F.L., and P.R. have received honoraria for speaking and for consulting from Roche. P.R. has received research grants from Roche. G.Z. has participated in meetings sponsored by or received travel funding from Roche. G.B. has participated in meetings sponsored by, received speaker honoraria, honoraria for consulting or travel funding from Roche. A.D.B. has received speaker honoraria and participated in meetings sponsored by or travel funding from Roche. T.B. has participated in meetings sponsored by and received honoraria (lectures, advisory boards, consultations) from Roche. His institution has received financial support in the last 12 months for participation in clinical trials in multiple sclerosis sponsored by Roche. M.K., L.S., H.H., R.T., F.Z., W.R., K.Z., I.W., A.S., M.G., M.M., K.R., S.W., J.H.A., and S.T. report no conflicts of interest relevant to this study."

"Laboratory material was partly funded by a Medical‐Scientific fund of the Major of the federal capital of Vienna (grant Covid003)."